Telix Pharmaceuticals (TLX) Other Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Other Non-Current Assets for 3 consecutive years, with $28.8 million the latest figure, recorded in Q4 2025.

• Quarterly Other Non-Current Assets fell 18.37% year-over-year to $28.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28.8 million (down 18.37% YoY) and the FY2025 annual result came in at $28.8 million, up 91.0% from the prior year.
• Other Non-Current Assets retreated to $28.8 million in Q4 2025 per TLX's latest filing, from $35.3 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for TLX reached as high as $35.3 million in Q4 2024 and fell as low as $413847.7 in Q4 2023.
• A 3-year average of $21.5 million and a median of $28.8 million in 2025 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 8432.42% — and 2025, when it declined 18.37%.
• Year by year, Other Non-Current Assets stood at $413847.7 in 2023, then soared by 8432.42% to $35.3 million in 2024, then dropped by 18.37% to $28.8 million in 2025.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $28.8 million, $35.3 million, and $413847.7 for Q4 2025, Q4 2024, and Q4 2023 respectively.